logo
The biggest pros and cons to consider before taking weight loss jabs

The biggest pros and cons to consider before taking weight loss jabs

Metro29-05-2025
In the 90s and 00s, slimming clubs were packed with people looking to shed the pounds.
Flash forward to today however, and Weight Watchers has filed for bankruptcy, as the meteoric rise of weight loss jabs saw the company struggling to compete.
Medications like Ozempic, Mounjaro, Wegovy and Rybelsu, previously used to treat diabetes, have exploded in popularity in recent years.
An estimated 500,000 Brits are now taking either Mounjaro or Wegovy (both of which are available on the NHS) and Simple Online Pharmacy claims demand is growing by up to 40% each month.
However, health secretary Wes Streeting warned that they shouldn't be seen as a quick 'cosmetic' fix, adding: 'These are serious medicines and should only be used responsibly and under medical supervision.'
So if you're considering weight loss jabs, we've compiled everything you need to know, as well as a look at the biggest pros and cons…
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
Administered as weekly jabs, these drugs – often called GLP-1 agonists – mimic the hormones our bodies release when we eat to help diabetics manage insulin levels.
But alongside regulating blood sugar, they also help with reducing appetite (so you feel less hungry throughout the day) and increasing feelings of fullness (so you eat less when you do).
In the UK, new rules mean you'll need to have a consultation with a specialist weight management service before being prescribed this kind of treatment.
This can be done through the NHS or privately, with the likes of Superdrug and Boots offering prescriptions online.
Metro asked Dr Suzanne Wylie, GP and medical adviser for IQdoctor, about the biggest pros and cons of weight loss injections. In terms of their benefits, here's what she had to say:
Weight loss
Unsurprisingly, weight loss drugs help you lose weight — but the amount is impressive, with studies showing patients typically see at least a 10% to 15% weight reduction.
'This can be transformative, especially for those with long-standing obesity where lifestyle interventions alone have failed,' says Dr Wylie.
⁠Reduction in obesity-related health issues
Dr Wylie explains: 'Weight loss of this magnitude is associated with a meaningful drop in the risk of type 2 diabetes, hypertension, sleep apnoea, and non-alcoholic fatty liver disease.
'There's also early evidence suggesting improved cardiovascular outcomes, even independent of weight loss. And for patients with pre-diabetes, these medications may delay or prevent progression to full-blown diabetes.'
Improved quality of life and mental health
Beyond the physical benefits, Dr Wylie says the 'positive impact on self-esteem and mood' caused by weight loss 'can create a virtuous cycle, making it easier to stay engaged with other aspects of health promotion, such as physical activity and social participation.'
⁠Support for patients who feel stuck
According to Dr Wylie, the helping hand these jabs provide can be a major boost for those who feel they've 'tried everything' without success.
She adds: 'As GPs, it's empowering to have another tool to offer that feels both compassionate and effective.'
Despite their benefits, there are a number of things to consider before taking weight loss drugs – including possible short-term and long-term side effects. Here's a look at what Dr Wylie considers the biggest downsides:
Side effects
'Gastrointestinal side effects are common, particularly during dose escalation,' she says, noting that these can include nausea, vomiting, diarrhoea, and constipation.
Dr Wylie also adds than in rare cases, 'there's a risk of pancreatitis or gallbladder issues.'
Weight loss drugs aren't something to mess around with – one side effect colloquially termed 'Ozempic face' is symbolic of that. But what is it? And what are the dangers of taking semaglutide incorrectly?
This phenomenon refers to sagging, ageing and lacklustre appearance of the facial skin and structures,' according to Dr Adil Sheraz, consultant dermatologist and British Skin Foundation spokesperson.
He said: 'The face has a layer of fat that essentially stretches the skin. Ozempic results in rapid weight loss and does so very effectively. This, of course, will lead to rapid loss of subcutaneous (under the skin) facial fat.
'The overlying skin however will not be able to shrink at the same rate, resulting in a sagging, droopy and wrinkled appearance.'
Dr Paul Jarrod Frank, a dermatologist in New York thought to have coined the phrase, told the New York Times he's started seeing Ozempic face 'every day' since these drugs hit the mainstream.
He said: 'A 50-year-old patient will come in, and suddenly, she's super-skinny and needs filler, which she never needed before. I look at her and say: 'How long have you been on Ozempic?' And I'm right 100 per cent of the time.'
This isn't necessarily specific to Ozempic. As Dr Sheraz explains, this change in facial features can occur with any type of rapid weight loss.
There are other potential complications to look out for too: Ozempic-style weight loss drugs were recently linked to symptoms of depression and suicidal ideation, as well as an increased risk of vision loss.
More worryingly, at the end of last year, the government issued a warning after 10 people died and 68 were admitted to hospital as a result of using the injections.
More than 7,000 reports of illness associated with the drugs had also been made, leading the Medicines and Healthcare products Regulatory Agency (MHRA) to publicly state they should not be used for 'unauthorised indications such as aesthetic weight loss'.
Long-term use
Unless you overhaul your habits, the results you see while taking these medications won't last long afterwards. More Trending
'Once stopped, weight regain is common unless there's been a concurrent and sustainable lifestyle change,' says Dr Wylie.
Costs
Only 'very specific patient groups' are entitled to weight loss jabs on the NHS, and 'privately, these medications are expensive, often over £200 a month.'
View More »
If you go private, it's important to seriously whether you can afford to keep your prescription going for long enough to see results.
Do you have a story to share?
Get in touch by emailing MetroLifestyleTeam@Metro.co.uk.
MORE: This daily bathroom habit isn't actually as harmless as it might seem
MORE: I've ditched coffee for this energy-boosting mushroom hydration drink
MORE: Feargal Sharkey shares shock cancer diagnosis after visiting doctor with sore throat
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Warning over 'dangerous' Listeria-contaminated cheeses
Warning over 'dangerous' Listeria-contaminated cheeses

Glasgow Times

time35 minutes ago

  • Glasgow Times

Warning over 'dangerous' Listeria-contaminated cheeses

The Spanish Food Safety Agency (AESAN) confirmed on 15 August 2025 that two types of French cheeses - Brie Meule (1 kg) and Camembert Viejo Porche - have tested positive for Listeria monocytogenes. The affected products have been distributed across Spain and are being withdrawn from sale. Spain is the most popular travel destination for Brits, with more than 15 million people from the UK visiting every year, and experts are warning holidaymakers to be extra careful this summer. Mark McShane, Food Hygiene Expert from Food Hygiene Certificate, says: 'Listeria is particularly dangerous because it can grow even at fridge temperatures. "Vulnerable groups such as pregnant women, the elderly, newborns, and those with weakened immune systems face the highest risk. If you have purchased these cheeses in Spain or brought them home from holiday, do not eat them under any circumstances.' AESAN has instructed that anyone in possession of the recalled products should not consume them and instead return them to the point of purchase. Symptoms of listeriosis may include: High fever Muscle aches Nausea Vomiting or diarrhoea In severe cases, the infection can spread beyond the digestive system and become life-threatening. Consumers who have eaten the affected products and feel unwell are advised to seek medical attention immediately. Mark McShane added: 'This is a timely reminder of how important food safety is when travelling abroad. "Always check for official recalls, practise strict hygiene when handling dairy products, and avoid high-risk foods if you are in a vulnerable group.' Recommended reading: What is a food recall? A food recall is when a food product may have to be withdrawn or recalled. A withdrawal is when unsafe food is removed from the supply chain before it has reached consumers. A recall is when unsafe food is removed from the supply chain and consumers are advised to take appropriate action, for example to return or dispose of the unsafe food.

Risk of cancer death drops by 11.1 per cent to record low
Risk of cancer death drops by 11.1 per cent to record low

The National

time2 hours ago

  • The National

Risk of cancer death drops by 11.1 per cent to record low

Statistics published by Public Health Scotland (PHS) have shown an 11.1% reduction in mortality rates since 2013, from 333.7 per 100,000 diagnoses to 296.8 per 100,000 in 2022. The data, published on Tuesday, showed the death rates from the illness are the lowest on record since 1998. READ MORE: Chemical company fined £100k after worker suffers 'serious burns' Health Secretary Neil Gray said: 'It is encouraging to see the risk of dying from cancer in Scotland is at a record low. This is down to the hard work of NHS staff, improved treatment options, and people reporting their symptoms at an earlier stage. 'We are determined to further improve cancer survival, reduce waiting times and provide excellent, equitably accessible care right across Scotland.' Due to Scotland's ageing population, 69% of all cancer-related deaths recorded in 2022 were individuals aged 70 or older. 'We are taking action to improve the awareness and earlier diagnosis of cancers, including expanding our Rapid Cancer Diagnostic Services and our investment of more than £14 million towards cancer waiting times this year', Gray continued. 'Reducing health inequalities is a clear ambition for this government. Cutting smoking rates is key to tackling lung cancer incidence in areas of deprivation – our world-leading tobacco control measures are helping us in our goal of a Tobacco-Free Scotland by 2034.' MSP for Rutherglen Clare Haughey welcomed the figures, praising the work of NHS staff and action taken by the Scottish Government to improve both treatment options and early detection initiatives. 'One death from cancer is one too many but these figures are welcome and show the real progress we are making to improve cancer survival under the SNP Government', Haughey said. READ MORE: Ayrshire trust in race to raise £200k for community ownership of B-listed church 'The fact that the likelihood of dying from cancer is at its lowest level on record is testament to the incredible work that staff in our NHS do throughout Scotland every day. 'The SNP is determined to go even further to improve cancer survival across Scotland by taking action to improve awareness and earlier diagnosis of cancers. This includes expanding our Rapid Cancer Diagnostic Services and investing more than £14 million to reduce cancer waiting times this year. 'Whilst other parties continually talk down our NHS, the SNP is getting on with the job of improving and extending lives by investing to tackle health inequalities and improve health outcomes for people right across Scotland.'

People with heart problems to get treatment online as NHS given green light
People with heart problems to get treatment online as NHS given green light

Daily Mirror

time2 hours ago

  • Daily Mirror

People with heart problems to get treatment online as NHS given green light

Seven million people in the UK could be affected by the new draft guidance People suffering from cardiac conditions could soon access rehabilitation programmes from the comfort of their own homes following new draft guidance unveiled on August 19. Six digital platforms have received conditional recommendations from the National Institute for Health and Care Excellence for deployment across the NHS, though the approach won't suit every patient. ‌ Activate Your Heart, D REACH-HF, Digital Heart Manual, Gro Health HeartBuddy, KiActiv and myHeart, are the approved platforms set to be used over a three-year period. They will be used while authorities compile data regarding their long-term effectiveness to tackle certain doubts surrounding the schemes. ‌ These digital rehabilitation services provide fitness regimens, nutritional guidance, learning resources, medicine oversight and mental health assistance. ‌ Certain platforms additionally feature wearable technology to track physical activity levels. Specialists claimed the schemes "offer real potential to transform" the delivery of this care category to individual patients. Approximately seven million Britons are thought to be impacted by cardiovascular illness covered by this fresh guidance, yet conventional rehabilitation schemes suffer from poor participation rates. During 2023, merely 41% of people with acute coronary syndrome, encompassing ailments such as heart attack and angina, took part in cardiac rehabilitation schemes across England. Just 13% of heart failure patients enrolled in the programmes during their recuperation. Rehabilitation for these conditions can slash the risk of additional heart troubles and hospital stays. Currently, these services are typically provided on the NHS through in-person consultations. Participation rates are notably poor amongst women, younger people, ethnic minorities, those in disadvantaged communities and others who find it difficult to attend face-to-face sessions. ‌ It's hoped that shifting this treatment online could boost the number of people getting involved. Dr Anastasia Chalkidou, healthtech programme director at Nice, said: "These digital platforms offer real potential to transform how cardiac rehabilitation is offered to people to meet their individual circumstances. "We know that traditional programmes aren't reaching everyone who could benefit - particularly women, younger patients and people from ethnic minority backgrounds. "The early data is promising and suggests, with safeguards in place, more people should now be given the opportunity to use these new technologies. ‌ "This three-year evidence collection period will give us the additional robust data we need to determine whether these innovations should be recommended as a permanent part of cardiac care." Nevertheless, NICE has acknowledged that the digital rehabilitation won't be appropriate for all patients. A qualified NHS healthcare professional will still be required to carry out a comprehensive clinical evaluation before recommending these platforms to individual patients. Following a three-year period of evidence collection, NICE will assess the data and make a decision on whether the technology can be regularly integrated into the NHS. A consultation on the conditional recommendation is currently in progress and will conclude on 3 September. NICE stated that seven other platforms – Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move – require further research before they can receive NHS funding.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store